Clinical Trials And Research Services Articles & Analysis
17 news found
CD Bioparticles, a leading manufacturer and supplier of numerous drug delivery products and services, has announced the launch of its new Tumor Organoid & CAF Co-culture services to provide researchers with a more physiologically relevant in vitro tumor model, enabling a deeper understanding of tumor-stromal interactions and the development of more effective cancer therapies. Although cancer ...
CD Bioparticles, a leading manufacturer and supplier of numerous drug delivery products and services, recently unveiled its significantly enhanced online ordering system. This latest update on the website aims to streamline the ordering process for customers, demonstrating CD Bioparticles' commitment that prioritize customer experience, while also creating greater workflow control, making it more ...
CD Bioparticles, a leading manufacturer and supplier of numerous drug delivery products and services, is thrilled to announce the launch of its new line of liposomes specifically designed for food applications, offering promising delivery systems to enhance the bioavailability, stability, and taste of various food ingredients. In the field of food science, liposomes have attracted much attention ...
The two companies collaborated with precision medicine clinical research organization (CRO) Precision for Medicine, which contributes its state-of-the-art, CAP-accredited, CLIA-certified laboratory services to Boundless Bio’s POTENTIATE Phase 1/2 clinical trial by successfully validating a proprietary ...
CD Bioparticles, a leading manufacturer and supplier of numerous drug delivery products and services, is proud to announce its expanded capabilities in Customized Liposomes. This advancement allows researchers and developers to leverage the power of liposome technology for a wider range of applications. Liposomes are small spherical artificial vesicles (typically 50-500 nm in diameter) composed ...
CD Bioparticles, a leading manufacturer and supplier of numerous drug delivery products and services, has recently expanded its low PDI polymer portfolio and announces its new offering of Polyolefin Family polymers with a wide range of properties that make them well-suited for a variety of drug delivery applications. Low dispersion index polymers are polymeric compounds with low molecular weight ...
CD Bioparticles, a leading manufacturer and supplier of numerous drug delivery products and services, has announced an expanded portfolio of Polydimethylsiloxane (PDMS) products, empowering researchers with versatile and biocompatible tools for groundbreaking discoveries. Polydimethylsiloxane is an elastomeric polymer with interesting properties for biomedical applications, including ...
CD Bioparticles, a leading manufacturer and supplier of numerous drug delivery products and services, has launched a new line of Locust Bean Gum with advanced technical platforms to help scientists advance biopharmaceutical research. Over the past few decades, researchers have been working on developing delivery systems that can reduce side effects while improving efficacy. Natural polymers are ...
CD Bioparticles, a leading manufacturer and supplier of numerous drug delivery products and services, recently introduced a line of highly efficient mRNA Transfection Reagents with low toxicity for research applications, including the mRNA Transfection Reagent, Stem mRNA Transfection Reagent, and mRNA/gRNA Transfection Reagent. mRNA transfection is the process of introducing and expressing mRNA ...
CD Bioparticles, a leading manufacturer and supplier of various drug delivery products and services, recently introduced a series of Magnetofection Reagents for gene expression. By utilizing the Lipofection and Magnetofection transfection techniques, these reagents are suitable for all types of nucleic acids, including plasmid DNA, linearized DNA, siRNA, oligonucleotides, double-stranded RNA, ...
Effective October 3rd, 2022, Laurie Smith has joined as Vice President of Product Strategy – Clinical Trial Matching. Laurie will be primarily focused on enhancing Inspirata’s suite of clinical trial matching solutions. ...
NEAAR-001 is a clinical trial of a precision nutrition-based diet that restricts specific amino acids that preclinical studies suggest are necessary for cancer growth. ...
ByxCures
Oxford, United Kingdom, 07 March, 2022: Orbit Discovery (Orbit), a ground-breaking peptide discovery company is pleased to announce the commencement of a partnership with WuXi AppTec, a leading global provider of R&D and manufacturing services that enable the global pharmaceutical and healthcare industry. Orbit will combine its leading peptide discovery platform and experience with WuXi ...
With entities based in Belgium, France, Spain and the UK, OncoDNA has built an outstanding network of cancer clinicians-researchers across Europe. The company will act as a primary lab partner, operating C2i’s whole-genome sequencing (WGS) and minimal-residual disease (MRD) cancer monitoring platform for European clinical research projects. ...
Balt, an innovative neurovascular company focused on developing, designing, and manufacturing solutions for treating complex, life-threatening conditions, including stroke, aneurysms, and arteriovenous malformations, today announced the appointment of Jeffrey Sachs as the Company's Chief Legal & Compliance Officer. Jeffrey Sachs joins the Balt team with over 25 years of experience in ...
“Although the number of oncology treatments has increased, there is more work to be done to ensure all patients are getting the best, most targeted therapies for their specific diseases. Clinical research must keep pace with the rate of scientific advancement, and that means clinical trials must be accessible to more ...
Establishes Thermo Fisher as a global leader in the attractive and high growth clinical research services industry Adds highly complementary services for the company's fastest growing end market Offers both meaningful cost and revenue synergies which will further accelerate growth Expected to be immediately and significantly accretive to Adjusted Earnings Per Share (EPS)¹ after close ...